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Fig 1. Patients with grade II-IV acute GVHD, DC: Donor T-cell Chimerism, MC:
Mixed T-cell Chimerism. Diagonal pattern in bar indicates patients progressing
to steroid resistant (SR) GVHD. P¼0.007.
Table 1
Workup panel results of suspected Myositis.* 10 excluded due to lack of
testing from n¼68.
No. of
patients
Muscle Biopsy Enzymes+ Antibodies+ EMG+ MRI/PET+
7 Positive 6/7 4/7 7/7 2/2
2 Equivocal 2/2 0/2 1/1 1/1
5 Negative 1/5 0/3 4/4 0/3
44 Not Done 30/40 7/23 8/16 11/19
58* TOTAL 39/54 11/35 20/28 14/25
Fig-1. Number of patients meeting Myositis criteria.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285 S275patients compared to MC patients. Early T-cell DC may be an
early predictor of development of steroid-resistant GVHD.
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Background: There is paucity of data on diagnostic criteria of
Myositis/Muscle chronic Graft-versus-Host disease [cGVHD]
due to rarity of the condition (<0.7% of all Allogeneic-
Hematopoietic-Stem-Cell-Transplants [HSCT]. Myalgias are
common after HSCT and confounding factors such as drugs
(statins, steroids etc.), infections (muscle abscess) and tumor
inﬁltration make diagnosis elusive. A diagnostic algorithm is
lacking.
Methods: We retrospectively analyzed all allogeneic-HSCTs
through the Mayo Clinic Database from Jan 1994-July 2013 to
search for cases of myositis in association with cGVHD using
terms “GVH”, “Muscle biopsy” and “Myositis”. Diagnostic
criteria utilized were 1) Muscle Biopsy; 2) Elevated Enzymes:
CK or Aldolase; 3) Serum Antibodies: ANA, anti-striated-
muscle, Anti Ro/Jo/La, Sm, Scl-70, RNP 4) EMG and 5) Imag-
ing: MRI or PET scan.
Results: Of 1058 screened allogeneic-HSCT, 68 were sus-
pected clinically of having myositis, mostly presenting as
focal or diffuse myalgias. 14 had muscle biopsies. 7 had
conﬁrmedmyositis (Age 43-66 yrs., median 47). Median time
to diagnosis was 19 months post-HSCT. All had cGVHD
involving at least one other organ. 5/7 had AML and 6/7
received a ﬂudarabine based conditioning. All biopsy positive
and 2 biopsy indeterminate patients met at least 2 additional
criteria besides biopsy (total criteria met 3). Of the 61 pa-
tients that were biopsy negative or not biopsied, none met 3
criteria (except 2 who could not be biopsied). 17 were tested
but met none of the criteria (excluded). Remaining met 2
criteria not deemed sufﬁcient for diagnosis. All biopsy
proven patients received prednisone treatment. 5 received
additional therapies including IVIG, ECP, Rituximab and
Sirolimus.
Conclusions: Muscle biopsy, while conﬁrmative, is invasive
and is rarely pursued (20%). Only half of the biopsies were
positive for myositis, likely due to patchy nature of theConﬂicts of Interest: Nonedisease. All biopsy proven myositis patients met 3 criteria.
Myositis as a component of cGVHD can be diagnosed using a
composite of autoantibodies, muscle enzymes, EMG and
imaging. This new criteria could be used to establish an al-
gorithm in delineating the need for muscle biopsy for sus-
pected myositis. (Fig 1 & Table 1).428
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